Table 1.

Treatment outcomes of PD-1/PD-L1 blockade combination therapies in classic Hodgkin lymphoma.

	Disease Condition	Combination Therapy	Phase	Number of Patients	ORR (%)	CRR (%)	PFS (%)	OS (%)	AE Grade 3–4	Reference
Frontline	Early-stage unfavorable	Nivo-AVD × 4 cycles	2	51	100	90	100% at 3 y	100% at 3 y	11%	[28,29]
		Nivo × 4 cycles, nivo-AVD × 2 cycles, followed by AVD × 2 cycles		50	98	94	98% at 3 y	100% at 3 y	7%
	Early-stage unfavorable, or advanced-stage	Nivo × 4 cycles, followed by AVD × 6 cycles	2	51	84	67	92% at 9 m	98% at 9 m	59%	[24]
	Early-stage unfavorable, or advanced-stage	Pem × 3 cycles, followed by AVD × 4–6 cycles	2	30	100	100	100% at 22.5 m	100% at 22.5 m	6%	[25,26]
	Advanced-stage	Nivo-AVD × 6 cycles	3	489	NA	NA	94% at 1 y	99% at 1 y	NA	[27]
		vs. BV-AVD × 6 cycles		487	NA	NA	86% at 1 y	98% at 1 y	NA
Relapsed/ Refractory	First salvage	Nivo-BV × 4 cycles	1/2	91	85	67	77% at 3 y	93% at 3 y	33%	[30,31]
	Post-ASCT consolidation	Nivo-BV × 8 cycles	2	59	NA	NA	92% at 2 y	98% at 2 y	NA	[32]
	First salvage	Nivo × 3 cycles, followed by nivo × 3 cycles or nivo-ICE. Pts. in CR/PR proceed to ASCT.	2	43	93	91	72% at 2 y	95% at 2 y	NA	[33]
	First salvage	Pem-ICE × 3 cycles, followed by pem × 1 cycle	2	37	97	87	87 at 2 y	95 at 2 y	NA	[34]
	Post multi-salvage	Nivo-ipilimumab	1b	31	74	23	not reached at 1 y	NA	29%	[35]

Abbreviations: nivo, nivolumab; pem, pembrolizumab; AVD, doxorubicin, vinblastine, and dacarbazine; ASCT, autologous stem cell transplantation; ICE, ifosfamide, carboplatin, and etoposide; BV, brentuximab vedotin; ORR, overall response rate; CRR, complete response rate; PR, partial response; PFS, progression-free survival; OS, overall survival; AE, adverse event; NA, not available.